To date, the clinical gene therapy trials for FA have all failed to achieve robust engraftment of corrected patient HSCs, although advances have been made in the ability of clinicians to transduce FA CD34+ cells with retroviral vectors [37, 152, 153]. This evidence concerns the gene CD34 and Friedreich ataxia.